Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
← catalyst calendarNCT05145127 · readout in 1,442 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
245estimated
Sites
75
Countries
Argentina, Australia, Brazil +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-11-17 | actual | When the study began enrolling |
| Primary completion | 2030-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-12-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hemophilia A
- Hemophilia B
Intervention
- Drug: PF-06741086 — also filed as marstacimab
Primary outcomes
what the primary-completion date above is the date OFNumber of subject reporting Adverse Events
measured Baseline up to 7 years
Number of subjects reporting Serious Adverse Events
measured Baseline up to 7 years
Incidence and severity of thrombotic events
measured Baseline up to 7 years
Incidence and severity of thrombotic microangiopathy
measured Baseline up to 7 years
Number of subjects reporting Disseminated intravascular coagulalopathy/consumption coagulopathy
measured Baseline up to 7 years
Incidence of clinically significant persistent NAb against marstacimab
measured Baseline up to 7 years
Incidence and severity of injection site reaction
measured Baseline up to 7 years
Clinically significant changes in vital signs from baseline
measured Baseline up to 7 years
Incidence of clinically significant laboratory value abnormalities
measured Baseline up to 7 years
Incidence of severe hypersensitivity and anaphylactic reactions
measured Baseline up to 7 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed